Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00217620 · ClinicalTrials.gov registry record · Phase 2
S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT00217620: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00217620 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 51 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00217620, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sorafenib works in treating patients with advanced soft tissue sarcomas.
Interventions
- DRUG sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2006-03 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00217620
The ClinicalTrials.gov registry entry for NCT00217620 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sorafenib is the first listed.
NCT00217620 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00217620 about?
NCT00217620 is a clinical study titled "S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas". RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sorafenib works in treating patients with advanced soft tissue sarcomas.
What is the current status of trial NCT00217620?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2006-03. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00217620?
The interventions under investigation include: sorafenib (DRUG).
Who is sponsoring clinical trial NCT00217620?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.